2. >>Business

Amneal Lines Up Launches As It Builds Out Biosimilars Business

Generics Sales Remain Flat In Q3, But Alymsys Bevacizumab Biosimilar Makes Solid Start

 
• By Dave Wallace

Fresh from introducing its first biosimilar in the US, Amneal expects two additional biosimilars to launch in the next couple of months as well as several further generics by year end. The firm also has its eye on future biosimilars opportunities where it can be early to market.

Dominoes lined up
Amneal is lining up multiple imminent biosimilar and generic launches • Source: Shutterstock

In the wake of launching its first biosimilar, Alymsys (bevacizumab-maly), in the US, Amneal is lining up two more biosimilars launches within the next couple of months as well as at least five further generics before the end of 2022.

The launches come as Amneal reported generics sales that were flat in the third quarter, advancing by just under 1% to $350m, with the nine-month total

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business